RT Journal Article
T1 IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
A1 Zhang, Meili
A1 Wen, Bernard
A1 Antón Hurtado, Olga María
A1 Yao, Zhengsheng
A1 Dubois, Sigrid
A1 Ju, Wei
A1 Sato, Noriko
A1 DiLillo, David
A1 Bamford, Richard
A1 Ravetch, Jeffrey
A1 Waldmann, Thomas
AB Previously we demonstrated that IL-15 by continuous infusion at 2 μg/kg/d for 10 days induced a 38-fold increase in circulating natural killer (NK) cells and a 358-fold increase in CD56 bright NK cells. In the present study we demonstrated that IL-15 enhanced antibody-dependent cellular cytotoxicity (ADCC) of tumor-directed monoclonal antibodies in two systems. Both NK cells and macrophages were required for optimal therapeutic responses. These studies support clinical trials of IL-15 combined with tumor-directed monoclonal antibodies. In translation of this study, a phase I trial of IL-15 combined with alemtuzumab has been opened for patients with adult T cell leukemia (ATL) NCT02689453.
PB National Academy of Sciences
SN 0027-8424
YR 2018
FD 2018
LK https://hdl.handle.net/20.500.14352/97029
UL https://hdl.handle.net/20.500.14352/97029
LA eng
NO Zhang, Meili, et al. «IL-15 Enhanced Antibody-Dependent Cellular Cytotoxicity Mediated by NK Cells and Macrophages». Proceedings of the National Academy of Sciences, vol. 115, n.o 46, noviembre de 2018. https://doi.org/10.1073/pnas.1811615115.
NO National Institute of Health (USA)
DS Docta Complutense
RD 26 abr 2025